BR112018000769A2 - anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos - Google Patents

anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos

Info

Publication number
BR112018000769A2
BR112018000769A2 BR112018000769-2A BR112018000769A BR112018000769A2 BR 112018000769 A2 BR112018000769 A2 BR 112018000769A2 BR 112018000769 A BR112018000769 A BR 112018000769A BR 112018000769 A2 BR112018000769 A2 BR 112018000769A2
Authority
BR
Brazil
Prior art keywords
methods
specific antibodies
hyperphosphorylated tau
tau specific
hyperphosphorylated
Prior art date
Application number
BR112018000769-2A
Other languages
English (en)
Inventor
Torleif Pedersen Jan
Østergaard Pedersen Lars
Claus Alfred Dächsel Justus
Abdur-Rasheed Asuni Ayodeji
Rosenqvist Nina
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1512211.2A external-priority patent/GB201512211D0/en
Priority claimed from GBGB1518375.9A external-priority patent/GB201518375D0/en
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of BR112018000769A2 publication Critical patent/BR112018000769A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

a presente invenção se refere a uma nova classe de anticorpo monoclonal que liga especificamente ao resíduo 396 da serina fosforilada em tau patológica hiperfosforilada (phf) (ps396), bem como aos métodos de utilização destas moléculas e seus fragmentos de ligação a tau no tratamento da doença de alzheimer e tauopatias.
BR112018000769-2A 2015-07-13 2016-07-12 anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos BR112018000769A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1512211.2A GB201512211D0 (en) 2015-07-13 2015-07-13 Agents, uses and methods
GB1512211.2 2015-07-13
GB1518375.9 2015-10-16
GBGB1518375.9A GB201518375D0 (en) 2015-10-16 2015-10-16 Agents,uses and methods
PCT/EP2016/066470 WO2017009308A2 (en) 2015-07-13 2016-07-12 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112018000769A2 true BR112018000769A2 (pt) 2018-09-25

Family

ID=56557664

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000769-2A BR112018000769A2 (pt) 2015-07-13 2016-07-12 anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos

Country Status (32)

Country Link
US (4) US10196439B2 (pt)
EP (1) EP3322442A2 (pt)
JP (1) JP6878395B2 (pt)
KR (1) KR20180030047A (pt)
CN (1) CN107847595B (pt)
AU (1) AU2016292892B2 (pt)
BR (1) BR112018000769A2 (pt)
CA (1) CA2990555A1 (pt)
CL (1) CL2018000096A1 (pt)
CO (1) CO2017013318A2 (pt)
CR (1) CR20180026A (pt)
DO (1) DOP2018000012A (pt)
EA (1) EA038703B1 (pt)
EC (1) ECSP18002644A (pt)
GE (1) GEP20227369B (pt)
HK (1) HK1254357A1 (pt)
IL (1) IL256791B (pt)
JO (1) JO3711B1 (pt)
MA (1) MA42446A (pt)
MX (1) MX2018000505A (pt)
NI (1) NI201800005A (pt)
NZ (1) NZ738595A (pt)
PE (1) PE20180607A1 (pt)
PH (1) PH12018500062A1 (pt)
RU (1) RU2727911C2 (pt)
SG (1) SG10202101343RA (pt)
SV (1) SV2018005611A (pt)
TN (1) TN2017000541A1 (pt)
TW (1) TWI741987B (pt)
UA (1) UA123862C2 (pt)
WO (1) WO2017009308A2 (pt)
ZA (1) ZA201800070B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121465B (zh) 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
SG10201911349YA (en) 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
PE20190227A1 (es) * 2016-07-12 2019-02-13 H Lundbeck As Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso
WO2018035137A1 (en) * 2016-08-15 2018-02-22 The Board Of Regents Of The University Of Texas System Volume control device for manually operated resuscitator and ventilation apparatus and method of use
JP2020500841A (ja) 2016-10-28 2020-01-16 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノンの投与を含む併用療法
CN109803658A (zh) 2016-10-28 2019-05-24 H.隆德贝克有限公司 包含用于治疗精神疾病和/或认知障碍的咪唑并吡嗪酮的组合治疗
EP3551220A1 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of use
KR102645073B1 (ko) 2016-12-07 2024-03-11 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
EP3565836A1 (en) * 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
TWI809562B (zh) 2017-10-16 2023-07-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
BR112019016815A2 (pt) 2017-12-14 2020-04-07 H Lundbeck As tratamentos de combinação que compreendem a administração de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
JP2021512602A (ja) * 2018-02-01 2021-05-20 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． タウに特異的に結合する結合分子
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau
CN113748343A (zh) 2019-03-28 2021-12-03 H.隆德贝克有限公司 pS396测定用于诊断TAU蛋白病的用途
WO2021211753A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
KR20230084508A (ko) 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물
EP4211172A1 (en) * 2020-09-11 2023-07-19 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
WO2022104136A2 (en) * 2020-11-12 2022-05-19 Children's Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment
IL303638A (en) 2020-12-16 2023-08-01 Voyager Therapeutics Inc tau binding compounds
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024067401A1 (zh) * 2022-09-26 2024-04-04 中美华世通生物医药科技(武汉)股份有限公司 包含Fc-高级脂肪酸链的超长效平台

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
DE69233723T2 (de) 1991-12-06 2009-02-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit
PT804070E (pt) 1993-03-09 2000-11-30 Genzyme Corp Isolamento de componentes de interesse a partir do leite.
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DK1150918T3 (da) 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
KR20020047098A (ko) 1999-07-29 2002-06-21 추후제출 ＨＥＲ2/ｎｅｕ에 대한 인간 모노클로날 항체
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007019273A2 (en) 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
EP2185592B1 (en) 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP3329932A1 (en) 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2778756A1 (en) 2009-10-26 2011-05-05 Otsuka Pharmaceutical Co., Ltd. Benzazepine compound
JP6371526B2 (ja) * 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
PL2627672T3 (pl) * 2010-10-11 2018-11-30 Biogen International Neuroscience Gmbh Ludzkie przeciwciała anty-tau
SG10201703771WA (en) * 2011-09-19 2017-06-29 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
EP2764022B9 (en) * 2011-10-07 2017-02-22 AC Immune S.A. Phosphospecific antibodies recognising tau
SG11201406347TA (en) 2012-04-05 2014-11-27 Ac Immune Sa Humanized tau antibody
RU2018132044A (ru) 2012-07-03 2018-10-19 Вашингтон Юниверсити Антитела против тау
AU2013302540B2 (en) 2012-08-16 2018-02-15 Ipierian, Inc. Methods of treating a tauopathy
CN105121465B (zh) 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
EP2986713A1 (en) * 2013-04-16 2016-02-24 Glykos Finland Oy A method for generating induced pluripotent stem cells
WO2016007414A1 (en) 2014-07-08 2016-01-14 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PE20190227A1 (es) 2016-07-12 2019-02-13 H Lundbeck As Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3565836A1 (en) 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Also Published As

Publication number Publication date
GEP20227369B (en) 2022-04-11
SG10202101343RA (en) 2021-03-30
EA201890039A1 (ru) 2018-08-31
CN107847595B (zh) 2021-09-24
MA42446A (fr) 2018-05-23
AU2016292892B2 (en) 2021-11-18
US10562962B2 (en) 2020-02-18
US11739140B2 (en) 2023-08-29
JP2018531580A (ja) 2018-11-01
EA038703B1 (ru) 2021-10-07
AU2016292892A1 (en) 2018-01-18
ZA201800070B (en) 2019-04-24
US20190177401A1 (en) 2019-06-13
WO2017009308A2 (en) 2017-01-19
ECSP18002644A (es) 2018-03-31
US20200190178A1 (en) 2020-06-18
TW201716436A (zh) 2017-05-16
US10196439B2 (en) 2019-02-05
JO3711B1 (ar) 2021-01-31
TWI741987B (zh) 2021-10-11
US20170015738A1 (en) 2017-01-19
SV2018005611A (es) 2018-02-23
RU2727911C2 (ru) 2020-07-24
RU2018100822A (ru) 2019-08-13
HK1254357A1 (zh) 2019-07-19
CR20180026A (es) 2018-03-08
IL256791B (en) 2022-09-01
CA2990555A1 (en) 2017-01-19
PE20180607A1 (es) 2018-04-09
CN107847595A (zh) 2018-03-27
CL2018000096A1 (es) 2018-07-06
PH12018500062A1 (en) 2018-07-09
NZ738595A (en) 2022-07-01
RU2018100822A3 (pt) 2019-12-26
CO2017013318A2 (es) 2018-05-21
US20210206843A1 (en) 2021-07-08
UA123862C2 (uk) 2021-06-16
KR20180030047A (ko) 2018-03-21
JP6878395B2 (ja) 2021-05-26
NI201800005A (es) 2018-10-19
TN2017000541A1 (en) 2019-04-12
US10934348B2 (en) 2021-03-02
MX2018000505A (es) 2018-04-30
IL256791A (en) 2018-03-29
WO2017009308A3 (en) 2017-04-06
DOP2018000012A (es) 2018-02-28
EP3322442A2 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
BR112018000769A2 (pt) anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos
BR112018004916A2 (pt) anticorpos específicos para tau hiperfosforilada e métodos de uso dos mesmos
BR112015006060A2 (pt) agentes de ligação kir3dl2
CO2017013356A2 (es) Anticuerpos de factor xi
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
CU20180024A7 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
BR112014019611A2 (pt) agentes de ligação mica
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
BR112012022102A2 (pt) polipeptídeos de ligação a a-beta.
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
EA202191666A1 (ru) Антитела к il-27 и их применение
BR112017010298A2 (pt) anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos
CR20190012A (es) Anticuerpos específicos para la tauy hiperfosforilada y sus métodos de uso
AR109258A1 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
AR105333A1 (es) Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos
EA201892570A1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
EA201991020A2 (ru) Применение семафорин-4d-связывающих молекул для лечения нейродегенеративных нарушений
DOP2012000266A (es) PROTEÍNAS QUE SE UNEN AL TNF-a

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]